WATERTOWN, Mass. -- (BUSINESS WIRE) -- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, will report its first quarter 2014 financial results on May 13, 2014. Dicerna will host a conference call and live audio webcast on May 13, 2014, at 4:30 p.m. (ET) to discuss the Company's financial results and provide a general business update.
To participate in the conference call, please dial 855-453-3834 (domestic) or 484-756-4306 (international) and refer to conference ID 44094909. To access the live webcast please visit the "Events & Presentations" page under the "Investors & Media" tab on Dicerna's website at www.dicerna.com.
An archived copy of the webcast will be available on Dicerna's website beginning approximately two hours after the conference call, and will be available on the website for at least 30 days after the call.
About Dicerna Pharmaceuticals, Inc.
Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas and intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in the prospectus related to the initial public offering, and in other filings that Dicerna may make with the SEC in the future. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.